AUTL (Autolus Therapeutics) Ending Cash Position: $132.42 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AUTL Autolus Therapeutics PLC AUTL
68 GF Score
Price $2.17
GF Value $21.93
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Autolus Therapeutics Ending Cash Position?

Autolus Therapeutics AUTL +2.61% 68 Ending Cash Position is $132.42 Mil as of Mar. 2026. GuruFocus rates AUTL with a GF Score™ of 68/100 and a GF Value™ of $21.93 (Possible Value Trap). The stock has 9 warning signs investors should review.

Autolus Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $132.42 Mil.

Autolus Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 ($87.62 Mil) to Dec. 2025 ($105.64 Mil) and increased from Dec. 2025 ($105.64 Mil) to Mar. 2026 ($132.42 Mil).

Autolus Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($240.34 Mil) to Dec. 2024 ($228.81 Mil) and declined from Dec. 2024 ($228.81 Mil) to Dec. 2025 ($105.64 Mil).

Autolus Therapeutics Ending Cash Position Related Terms

Autolus Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Autolus Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autolus Therapeutics Ending Cash Position Chart

Autolus Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 310.68 382.76 240.34 228.81 105.64

Autolus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.25 125.33 87.62 105.64 132.42
AUTL
68GF Score
Autolus Therapeutics PLC AUTL
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autolus Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Autolus Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=228.805+-123.17
=105.64

Autolus Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=105.635+26.783
=132.42

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $132.42 Mil mean?
Autolus Therapeutics (AUTL) has a Ending Cash Position of $132.42 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Autolus Therapeutics and its competitors.
Is Autolus Therapeutics' Ending Cash Position too high?
Autolus Therapeutics' current Ending Cash Position is $132.42 Mil. Overall, Autolus Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Ending Cash Position compare to TENX and IPSC?
Autolus Therapeutics' Ending Cash Position of $132.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Autolus Therapeutics and its competitors. Autolus Therapeutics's current Ending Cash Position is $132.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (AUTL) is currently considered Possible Value Trap. The stock's GF Value™ is $21.93, compared to a current price of $2.17 — trading 90.1% below its estimated fair value. The current Ending Cash Position is $132.42 Mil. Autolus Therapeutics' overall GF Score™ is 68/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Autolus Therapeutics (AUTL), the current Ending Cash Position is $132.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Autolus Therapeutics (AUTL) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of $2.17 is trading 90.1% below its estimated GF Value™ of $21.93. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for AUTL:

  • Ending Cash Position: $132.42 Mil
  • GF Value™: $21.93 vs. price of $2.17 (90.1% below fair value)
  • GF Score™: 68/100 with 9 warning signs

No single metric tells the full story. See the AUTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges 6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score

Get the complete analysis for AUTL

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.17
Price
$21.93
GF Value